{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:41:40Z","timestamp":1789580500900,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07613-w","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T14:34:47Z","timestamp":1766673287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway"],"prefix":"10.1186","volume":"23","author":[{"given":"Jian","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"7613_CR1","doi-asserted-by":"crossref","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers 2023, 9(1).","DOI":"10.1038\/s41572-023-00468-9"},{"issue":"6","key":"7613_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Epidemiology, Screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5(6):628\u201339.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"7613_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11912-025-01645-7","volume":"27","author":"S Smani","year":"2025","unstructured":"Smani S, Dubois J, Zhao K, Sutherland R, Rahman SN, Humphrey P, Hesse D, Tan WS, Martin D, Lokeshwar SD, et al. Advancements in the Diagnosis, Treatment, and risk stratification of Non-Muscle invasive bladder cancer. Curr Oncol Rep. 2025;27(3):236\u201346.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"7613_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41585-023-00842-y","volume":"21","author":"E Grobet-Jeandin","year":"2024","unstructured":"Grobet-Jeandin E, Lenfant L, Pinar U, Parra J, Mozer P, Renard-Penna R, Thibault C, Roupr\u00eat M, Seisen T. Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases. Nat Rev Urol. 2024;21(6):339\u201356.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"7613_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s11912-025-01657-3","volume":"27","author":"S Popli","year":"2025","unstructured":"Popli S, Durant AM, Tyson M, Singh P. Current state of bladder preservation in high grade Non-Muscle invasive bladder cancer and localized muscle invasive bladder cancer. Curr Oncol Rep. 2025;27(6):761\u201373.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"7613_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.molmed.2024.04.004","volume":"30","author":"R Ben -David","year":"2024","unstructured":"Ben -David R, Galsky MD, Sfakianos JP. Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer. Trends Mol Med. 2024;30(7):686\u201397.","journal-title":"Trends Mol Med"},{"issue":"10364","key":"7613_CR7","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712\u201321.","journal-title":"Lancet"},{"issue":"5","key":"7613_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00345-020-03474-8","volume":"39","author":"JL Pfail","year":"2021","unstructured":"Pfail JL, Katims AB, Alerasool P, Sfakianos JP. Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World J Urol. 2021;39(5):1319\u201329.","journal-title":"World J Urol"},{"key":"7613_CR9","doi-asserted-by":"crossref","unstructured":"Liu JW, Gao Y, Song C, Liao WB, Meng LC, Yang SX, Xiong YH. Immunotherapeutic prospects and progress in bladder cancer. J Cell Mol Med 2024, 28(5).","DOI":"10.1111\/jcmm.18101"},{"issue":"13","key":"7613_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1089\/ars.2021.0018","volume":"35","author":"V Jha","year":"2021","unstructured":"Jha V, Kumari T, Manickam V, Assar Z, Olson KL, Min JK, Cho J. ERO1-PDI redox signaling in health and disease. Antioxid Redox Sign. 2021;35(13):1093\u2013115.","journal-title":"Antioxid Redox Sign"},{"key":"7613_CR11","doi-asserted-by":"crossref","unstructured":"Zito E, Guarrera L, Janssen-Heininger YMW. Fingerprint of the oxido-reductase ERO1: a protein disulfide bond producer and supporter of cancer. Bba-Rev Cancer 2024, 1879(1).","DOI":"10.1016\/j.bbcan.2023.189027"},{"key":"7613_CR12","doi-asserted-by":"crossref","unstructured":"Benham AM, van Lith M, Sitia R, Braakman I. Ero1-PDI interactions, the response to redox flux and the implications for disulfide bond formation in the mammalian endoplasmic reticulum. Philos T R Soc B 2013, 368(1617).","DOI":"10.1098\/rstb.2011.0403"},{"key":"7613_CR13","doi-asserted-by":"crossref","unstructured":"Chen P, Chen YH, Sharma A, Maria AGC, Schmidt-Wolf IGH. Inhibition of ERO1L induces autophagy and apoptosis via Endoplasmic reticulum stress in colorectal cancer. Cell Signal 2025, 127.","DOI":"10.1016\/j.cellsig.2024.111560"},{"key":"7613_CR14","doi-asserted-by":"crossref","unstructured":"Shergalis AG, Hu S, Bankhead IA, Neamati N. Role of the ERO1-PDI interaction in oxidative protein folding and disease. Pharmacol Therapeut 2020, 210.","DOI":"10.1016\/j.pharmthera.2020.107525"},{"key":"7613_CR15","doi-asserted-by":"crossref","unstructured":"Tay AHM, Cinotti R, Sze NSK, Lundqvist A. Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma. Front Immunol 2023, 14.","DOI":"10.3389\/fimmu.2023.1264012"},{"key":"7613_CR16","doi-asserted-by":"crossref","unstructured":"Varone E, Retini M, Cherubini A, Chernorudskiy A, Marrazza A, Guidarelli A, Cagnotto A, Beeg M, Gobbi M, Fumagalli S et al. Small molecule-mediated Inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment. Cell Death Dis 2025, 16(1).","DOI":"10.1038\/s41419-025-07426-1"},{"key":"7613_CR17","doi-asserted-by":"crossref","unstructured":"Voronkova MA, Johnson B, Gandhi N, Koomen JM, Patrick M, Bhupathi SS, Wu VM, Elliott A, Vanderwalde A, Halmos B et al. ERO1A levels are a prognostic indicator in EGFR mutated Non small cell lung cancer. Npj Precis Oncol 2024, 8(1).","DOI":"10.1038\/s41698-024-00736-1"},{"issue":"18","key":"7613_CR18","doi-asserted-by":"publisher","first-page":"8400","DOI":"10.7150\/thno.45124","volume":"10","author":"JF Zhang","year":"2020","unstructured":"Zhang JF, Yang JY, Lin CY, Liu W, Huo YM, Yang MW, Jiang SH, Sun YW, Hua R. Endoplasmic reticulum stress-dependent expression of ERO1L promotes aerobic Glycolysis in pancreatic cancer. Theranostics. 2020;10(18):8400\u201314.","journal-title":"Theranostics"},{"key":"7613_CR19","doi-asserted-by":"crossref","unstructured":"Zilli F, Ramos PM, Maur PAD, Jehanno C, Sethi A, Coissieux MM, Eichlisberger T, Sauteur L, Rouchon A, Bonapace L et al. The NFIB-ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells. Embo Mol Med 2021, 13(4).","DOI":"10.15252\/emmm.202013162"},{"key":"7613_CR20","doi-asserted-by":"crossref","unstructured":"Liu LH, Li SN, Qu Y, Bai H, Pan XY, Wang J, Wang ZJ, Duan JC, Zhong J, Wan R et al. Ablation of ERO1A induces lethal Endoplasmic reticulum stress responses and Immunogenic cell death to activate anti-tumor immunity. Cell Rep Med 2023, 4(10).","DOI":"10.1016\/j.xcrm.2023.101206"},{"key":"7613_CR21","doi-asserted-by":"crossref","unstructured":"Hu WM, Liu SQ, Zhu KF, Li W, Yang ZJ, Yang Q, Zhu ZC, Chang J. The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK\/STAT and inhibits pancreatic cancer invasion and metastasis. Int Immunopharmacol 2023, 121.","DOI":"10.1016\/j.intimp.2023.110505"},{"key":"7613_CR22","doi-asserted-by":"crossref","unstructured":"Huang H, Pan YW, Mai QW, Zhang CY, Du QQ, Liao YD, Qin SH, Chen YL, Huang JM, Li J et al. Targeting CDCP1 boost CD8\u2009+\u2009T cells-mediated cytotoxicity in cervical cancer via the JAK\/STAT signaling pathway. J Immunother Cancer 2024, 12(10).","DOI":"10.1136\/jitc-2024-009416"},{"key":"7613_CR23","doi-asserted-by":"crossref","unstructured":"Peng D, Yang WP, Tang TY, He AB, Xu X, Jing TL, Xia D. PLA2G7 promotes immune evasion of bladder cancer through the JAK-STAT-PDL1 axis. Cell Death Dis 2025, 16(1).","DOI":"10.1038\/s41419-025-07593-1"},{"issue":"4","key":"7613_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/tox.23440","volume":"37","author":"Y Feng","year":"2022","unstructured":"Feng Y, Wang JB, Cai B, Bai XM, Zhu YR. Ivermectin accelerates autophagic death of glioma cells by inhibiting Glycolysis through blocking GLUT4 mediated JAK\/STAT signaling pathway activation. Environ Toxicol. 2022;37(4):754\u201364.","journal-title":"Environ Toxicol"},{"key":"7613_CR25","doi-asserted-by":"crossref","unstructured":"Kalampounias G, Zafeiropoulou K, Androutsopoulou T, Alexis S, Symeonidis A, Katsoris P. The transcription axes ERK-Elk1, JNK-cJun, and JAK-STAT promote autophagy activation and proteasome inhibitor resistance in prostate cancer cells. Curr Issues Mol Biol 2025, 47(5).","DOI":"10.3390\/cimb47050352"},{"issue":"19","key":"7613_CR26","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1111\/jcmm.17863","volume":"27","author":"LZ Li","year":"2023","unstructured":"Li LZ, Zhang YL, Hu WM, Zou F, Ning JZ, Rao T, Ruan Y, Yu WM, Cheng F. MTHFD2 promotes PD-L1 expression via activation of the JAK\/STAT signalling pathway in bladder cancer. J Cell Mol Med. 2023;27(19):2922\u201336.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"7613_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MOU.0000000000001182","volume":"34","author":"I Ertl","year":"2024","unstructured":"Ertl I, Shariat SF, Berger W, Englinger B. Preclinical models for bladder cancer therapy research. Curr Opin Urol. 2024;34(4):244\u201350.","journal-title":"Curr Opin Urol"},{"key":"7613_CR28","doi-asserted-by":"crossref","unstructured":"Gilyazova I, Enikeeva K, Rafikova G, Kagirova E, Sharifyanova Y, Asadullina D, Pavlov V. Epigenetic and immunological features of bladder cancer. Int J Mol Sci 2023, 24(12).","DOI":"10.3390\/ijms24129854"},{"key":"7613_CR29","doi-asserted-by":"crossref","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. Bmj-Brit Med J 2024, 384.","DOI":"10.1136\/bmj-2023-076743"},{"issue":"6","key":"7613_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, van de Putte EEF, Horenblas S, Drabick JJ. Neoadjuvant chemotherapy for Muscle-Invasive bladder cancer: A systematic review and Two-Step Meta-Analysis. Oncologist. 2016;21(6):708\u201315.","journal-title":"Oncologist"},{"issue":"1","key":"7613_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-015-2052-6","volume":"73","author":"DS Schwarz","year":"2016","unstructured":"Schwarz DS, Blower MD. The Endoplasmic reticulum: structure, function and response to cellular signaling. Cell Mol Life Sci. 2016;73(1):79\u201394.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"7613_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1089\/ars.2011.4418","volume":"16","author":"K Araki","year":"2012","unstructured":"Araki K, Inaba K. Structure, Mechanism, and evolution of Ero1 family enzymes. Antioxid Redox Sign. 2012;16(8):790\u20139.","journal-title":"Antioxid Redox Sign"},{"key":"7613_CR33","doi-asserted-by":"crossref","unstructured":"Nie H, Luo CC, Liao KL, Xu JS, Wang XZ. Seven Glycolysis-Related genes predict the prognosis of patients with pancreatic cancer. Front Cell Dev Biol 2021, 9.","DOI":"10.3389\/fcell.2021.647106"},{"key":"7613_CR34","doi-asserted-by":"crossref","unstructured":"Fu ZQ, Chen KL, Zheng F, Gong WG, Chao D, Lu C. FCGBP promotes ovarian cancer progression via activation of IL-6\/JAK-STAT signaling pathway. J Transl Med 2025, 23(1).","DOI":"10.1186\/s12967-025-06854-z"},{"issue":"6","key":"7613_CR35","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s10120-022-01319-4","volume":"25","author":"JY Zhou","year":"2022","unstructured":"Zhou JY, Li TY, Chen H, Jiang YM, Zhao YD, Huang JT, Chen ZJ, Tang XC, Huang ZZ, Yang ZL. ADAMTS10 inhibits aggressiveness via JAK\/STAT\/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer. Gastric Cancer. 2022;25(6):1002\u201316.","journal-title":"Gastric Cancer"},{"key":"7613_CR36","doi-asserted-by":"crossref","unstructured":"Liu SZ, Yao SJ, Yang H, Liu SJ, Wang YJ. Autophagy: regulator of cell death. Cell Death Dis 2023, 14(10).","DOI":"10.1038\/s41419-023-06154-8"},{"issue":"4","key":"7613_CR37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728\u201341.","journal-title":"Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07613-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T21:02:52Z","timestamp":1767042172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07613-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7613"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07613-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethics Committee of the First Affiliated Hospital of Yangtze University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of this study agreed with the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1427"}}